3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
venetoclax
21
Cyclophosphamide
14
Cytarabine
12
Azacitidine
8
fludarabine
7
Dexamethasone
5
Daunorubicin
5
ruxolitinib
4
revumenib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
quizartinib
3
pirtobrutinib
3
gamma-Globulins
3
fludarabine phosphate
3
blinatumomab
3
Tacrolimus
3
Rituximab
3
Palliative Care
3
Inotuzumab Ozogamicin
3
Granulocyte Colony-Stimulating Factor
3
Decitabine
3
Ciprofloxacin
3
Blood Specimen Collection
3
zanubrutinib
2
ponatinib
2
pembrolizumab
2
ibrutinib
2
aldesleukin
2
acalabrutinib
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled